Transmitted antiretroviral drug resistance in New York State, 2006-2008: Results from a new surveillance system

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Readhead, Adam C ^a   Gordon, Daniel E ^b   Wang, Zhengyan ^b   Anderson, Bridget J ^b   Brousseau, Kathleen S ^b   Kouznetsova, Maria A ^b   Forgione, Lisa A ^a   Smith, Lou C ^b   Torian, Lucia V ^a  

^a NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^b NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS LOPINAVIR PLUS RITONAVIR PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADOLESCENT; ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CROSS-SECTIONAL STUDY; FEMALE; GENOTYPE; HEALTH SURVEY; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MEDICAL CARE; NONHUMAN; RISK FACTOR; UNITED STATES; VIRUS MUTATION;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; CHILD; DEMOGRAPHY; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; NEW YORK; POPULATION SURVEILLANCE; YOUNG ADULT;

EID: 84864655970     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040533     Document Type: Article

References (43)

1. Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA, et al. ((2008)) Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 197(6): 867-870.
2. Borroto-Esoda K, Waters JM, Bae AS, Harris JL, Hinkle JE, et al. ((2007)) Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz. AIDS Res Hum Retroviruses 23(8): 988-995.
3. Shet A, Berry L, Mohri H, Mehandru S, Chung C, et al. ((2006)) Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr 41(4): 439-446.
4. Markowitz M, Mohri H, Mehandru S, Shet A, Berry L, et al. ((2005)) Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet 365(9464): 1031-1038.
5. Torian LV, Blank S, Kellerman SE, Frieden TR, Ho DD, et al. ((2006)) Investigation of a new diagnosis of multidrug-resistant, dual-tropic HIV-1 infection - New York City. MMWR Morb Mortal Wkly Rep 55(29): 793-796.
6. Blick G, Kagan RM, Coakley E, Petropoulos C, Maroldo L, et al. ((2007)) The probable source of both the primary multidrug-resistant (MDR) HIV-1 strain found in a patient with rapid progression to AIDS and a second recombinant MDR strain found in a chronically HIV-1-infected patient. J Infect Dis 195(9): 1250-1259.
7. State of New York. Code of Administrative Rules and Regulations (2000) Vol Title 10 Part 63.
8. State of New York. Public Health Law (1998) Vol Article 21, Title 3.
9. State of New York. Public Health Law (1988) Vol Article 27-F.
10. State of New York. Public Health Law (1983) Vol Article 21.
11. State of New York. Code of Administrative Rules and Regulations (2006) Notice of Adoption, Title 10, Part 63. ed.: New York Register.
12. State of New York. Code of Administrative Rules and Regulations (2005) Notice of Emergency Rule Making, Title 10 Part 63. ed.: New York Register.
13. Torian LV, Henning KJ, Kellerman SE, Frieden TR, ((2007)) Striving toward comprehensive HIV/AIDS surveillance: the view from New York City. Public Health Rep 122 Suppl 1: 4-6.
14. Torian LV, Wiewel EW, Liu KL, Sackoff JE, Frieden TR, ((2008)) Risk factors for delayed initiation of medical care after diagnosis of human immunodeficiency virus. Arch Intern Med 168(11): 1181-1187.
15. New York State Department of Health, Bureau of HIV/AIDS Epidemiology (2008) New York State HIV/AIDS Surveillance Report.
16. Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, et al. ((2010)) Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 24(8): 1203-1212.
17. Centers for Disease Control, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (2007) Annual Report 2007.
18. Department of Health and Human Services (2007) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available: http://www.aidsinfo.nih.gov/guidelines. Accessed 2010 Nov 12.
19. http://www.hiv.lanl.gov/content/sequence/HIV. Accessed 2010 Nov 12.
20. Liu TF, Shafer RW, ((2006)) Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 42(11): 1608-1618.
21. HIV Drug Resistance database. Available: http://www.hivdb.stanford.edu. Accessed 2010 Nov 12.
22. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, et al. ((2009)) Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 4(3): e4724.
23. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. ((2010)) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363(27): 2587-2599.
24. Youmans E, Tripathi A, Albrecht H, Gibson JJ, Duffus WA, ((2011)) Transmitted antiretroviral drug resistance in individuals with newly diagnosed HIV infection: South Carolina 2005-2009. South Med J 104(2): 95-101.
25. Department of Health and Human Services (2006) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available: www.hiv.lanl.gov. Accessed 2010 Nov 12.
26. Sohler NL, Li X, Cunningham CO, ((2009)) Gender disparities in HIV health care utilization among the severely disadvantaged: can we determine the reasons? AIDS Patient Care STDS 23(9): 775-783.
27. Mimiaga MJ, Reisner SL, Bland S, Skeer M, Cranston K, et al. ((2009)) Health system and personal barriers resulting in decreased utilization of HIV and STD testing services among at-risk black men who have sex with men in Massachusetts. AIDS Patient Care STDS 23(10): 825-835.
28. Smedley BD (2003) ed (2003) Unequal Treatment: confronting racial and ethnic disparities in health care. Washington, DC: National Academy Press.
29. SPREAD Programme ((2008)) Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 22(5): 625-635.
30. Cane P, Chrystie I, Dunn D, Evans B, Geretti Am, et al. ((2005)) Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ. 331(7529): 1368.
31. Descamps D, Chaix ML, Andre P, Brodard V, Cottalorda J, et al. ((2005)) French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr 38(5): 545-552.
32. Grant EC, ((2002)) Hormone replacement therapy and risk of breast cancer. JAMA 287 (18): 2360; author reply 2361.
33. Hurt CB, McCoy SI, Kuruc J, Nelson J, Kerkau M, et al. ((2009)) Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007. Antivir Ther 14(5): 673-678.
34. Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, et al. ((2010)) Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PLoS One 5(12): e15510.
35. Jayaraman GC, Archibald CP, Kim J, Rekart ML, Singh AE, et al. ((2006)) A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr 42(1): 86-90.
36. Ross L, Lim ML, Liao Q, Wine B, Rodriguez AE, et al. ((2007)) Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naive HIV-infected individuals from 40 United States cities. HIV Clin Trials 8(1): 1-8.
37. Truong HM, Grant RM, McFarland W, Kellogg T, Kent C, et al. ((2006)) Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS 20(17): 2193-2197.
38. Yerly S, von Wyl V, Ledergerber B, Böni J, Schupbach J, et al. ((2007)) Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 21(16): 2223-2229.
39. Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, et al. ((2004)) The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 189(12): 2174-2180.
40. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, et al. ((2002)) Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347(6): 385-394.
41. McDavid K, McKenna MT, ((2006)) HIV/AIDS risk factor ascertainment: A critical challenge. AIDS Patient Care STD 20(4): 285-292.
42. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, et al. ((2008)) Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 5(7): e158.
43. White House Office of National AIDS Policy (2010) National HIV/AIDS strategy for the United States. Available: http://aids.gov/federal-resources/policies/national-hiv-aids-strategy/nhas.pdf. Accessed 2011 Mar 28.